GENETICALLY ENGINEERED ORAL VACCINES AND CARIES IMMUNITY

基因工程口服疫苗和龋齿免疫

基本信息

项目摘要

Dental caries is an infectious disease in which the major etiologic agents in humans are Streptococcus mutans and Streptococcus sobrinus. Studies aimed at inducing immunity against infectious diseases, including dental caries, have provided valuable information on microbial antigens important in inducing protective responses; on the role of IgA antibodies in defense against infections which invade or colonize surfaces bathed by external secretions; and on the mechanisms involved in inducing immune responses. Concurrent with these studies, the advancements in recombinant DNA technology and gene cloning have led to additional information on microbial gene products important in virulence and to the development of novel vaccines. The overall goal of this project is to define mechanisms by which mucosal vaccines consisting of recombinant, avirulent Salmonella strains expressing cloned genes of mutans streptococci, with and without adjuvant, induce specific immune responses. Specifically, we will: l) Determine the effectiveness of Salmonella expressed cloned B subunit of cholera toxin (CTB) in promoting immune responses to co-expressed cloned antigens of mutans streptococci. The levels and isotype of antibodies to the cloned antigens in serum and external secretions of mice and rats immunized orally with Salmonella expressing chimeric proteins will be measured by ELISA to determine the immunogenic and adjuvant properties of the different types of fusions between antigen and CTB in vivo. Analysis of caries activity in a rat model will assess the protective effect of the responses. These studies will determine which structural type of chimeric protein, when expressed by Salmonella in vivo, is most effective in promoting salivary IgA antibody responses protective against mutans streptococci. 2) Determine the effect of the Salmonella vaccine strain, vector, and promoter on the expression of cloned antigen of mutans streptococci and on the induction of immune responses. The amount of cloned antigen of mutans streptococci produced by Salmonella mutant strains containing expression vectors with different promoters and replicons will be measured by ELISA. Stability of the expression vectors will be assessed by microbiologic detection of Salmonella in tissues of mice orally-immunized with the Salmonella vaccine. The level and isotype of antibodies to the cloned antigen in serum and external secretions of animals orally immunized with a Salmonella strain containing different vectors will be measured to determine if differences exist in the magnitude and duration of the mucosal immune responses and in protection against infection by mutans streptococci. These studies will determine the effect of the vector replicon on the in vivo expression of cloned protein and on the induction of immune responses, and whether immune responses induced by the in vivo expression of cloned protein under the control of a constitutive promoter (trc) versus one induced in an anaerobic environment (nirB) are of greater magnitude and longer duration. 3) Determine the effect of route of immunization with a recombinant Salmonella vaccine on the magnitude and protective capability of the salivary IgA antibody response. The level of IgA antibodies to the cloned antigen in saliva in animals immunized by the oral or intranasal route will be measured by ELISA to determine which route of immunization induces the highest salivary IgA antibody response protective against infection by mutans streptococci. The results of these studies will be relevant in establishing the practicability of Salmonella vaccine delivery systems for the induction of protective immune responses against mucosal pathogens including those associated with the oral cavity.
龋齿是一种感染性疾病,其中的主要病原

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Suzanne M. Michalek其他文献

Cellular events leading to immunity following ingestion of food antigen
  • DOI:
    10.1016/s0091-6749(73)80082-x
  • 发表时间:
    1973-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Richard M. Rothberg;Sumner C. Kraft;Suzanne M. Michalek
  • 通讯作者:
    Suzanne M. Michalek
Polymer vesicles for the delivery of inhibitors of cariogenic biofilm
  • DOI:
    10.1016/j.dental.2024.09.006
  • 发表时间:
    2024-11-01
  • 期刊:
  • 影响因子:
  • 作者:
    Parmanand Ahirwar;Veronika Kozlovskaya;Piyasuda Pukkanasut;Pavel Nikishau;Sarah Nealy;Gregory Harber;Suzanne M. Michalek;Linto Antony;Hui Wu;Eugenia Kharlampieva;Sadanandan E. Velu
  • 通讯作者:
    Sadanandan E. Velu

Suzanne M. Michalek的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Suzanne M. Michalek', 18)}}的其他基金

Development of a Mucosal Vaccine Against F. tularensis
土拉弗朗西斯粘膜疫苗的研制
  • 批准号:
    6864867
  • 财政年份:
    2003
  • 资助金额:
    $ 23.3万
  • 项目类别:
Development of a Mucosal Vaccine Against F. tularensis
土拉弗朗西斯粘膜疫苗的研制
  • 批准号:
    6798161
  • 财政年份:
    2003
  • 资助金额:
    $ 23.3万
  • 项目类别:
Development of a Mucosal Vaccine Against F. tularensis
土拉弗朗西斯粘膜疫苗的研制
  • 批准号:
    7029667
  • 财政年份:
    2003
  • 资助金额:
    $ 23.3万
  • 项目类别:
Development of a Mucosal Vaccine Against Francisella tularensis
土拉弗朗西斯菌粘膜疫苗的研制
  • 批准号:
    7209733
  • 财政年份:
    2003
  • 资助金额:
    $ 23.3万
  • 项目类别:
Development of a Mucosal Vaccine Against F. tularensis
土拉弗朗西斯粘膜疫苗的研制
  • 批准号:
    6689492
  • 财政年份:
    2003
  • 资助金额:
    $ 23.3万
  • 项目类别:
BACTEROIDES LPS/CYTOKINE REGULATION IN INFLAMED GINGIVAL TISSUE
发炎牙龈组织中拟杆菌脂多糖/细胞因子的调节
  • 批准号:
    6104731
  • 财政年份:
    1998
  • 资助金额:
    $ 23.3万
  • 项目类别:
BACTEROIDES LPS/CYTOKINE REGULATION IN INFLAMED GINGIVAL TISSUE
发炎牙龈组织中拟杆菌脂多糖/细胞因子的调节
  • 批准号:
    6270281
  • 财政年份:
    1997
  • 资助金额:
    $ 23.3万
  • 项目类别:
GENETICALLY ENGINEERED ORAL VACCINES AND CARIES IMMUNITY
基因工程口服疫苗和龋齿免疫
  • 批准号:
    2130299
  • 财政年份:
    1996
  • 资助金额:
    $ 23.3万
  • 项目类别:
Genetically Engineered Oral Vaccines & Caries Immunity
基因工程口服疫苗
  • 批准号:
    6708881
  • 财政年份:
    1996
  • 资助金额:
    $ 23.3万
  • 项目类别:
Genetically Engineered Oral Vaccines & Caries Immunity
基因工程口服疫苗
  • 批准号:
    6634618
  • 财政年份:
    1996
  • 资助金额:
    $ 23.3万
  • 项目类别:

相似海外基金

Synthetic glycan conjugates with bacteriophage Qbeta for broad spectrum anti-salmonella vaccines
用于广谱抗沙门氏菌疫苗的合成聚糖与噬菌体 Qbeta 缀合物
  • 批准号:
    10432065
  • 财政年份:
    2019
  • 资助金额:
    $ 23.3万
  • 项目类别:
Synthetic glycan conjugates with bacteriophage Qbeta for broad spectrum anti-salmonella vaccines
用于广谱抗沙门氏菌疫苗的合成聚糖与噬菌体 Qbeta 缀合物
  • 批准号:
    9978709
  • 财政年份:
    2019
  • 资助金额:
    $ 23.3万
  • 项目类别:
Synthetic glycan conjugates with bacteriophage Qbeta for broad spectrum anti-salmonella vaccines
用于广谱抗沙门氏菌疫苗的合成聚糖与噬菌体 Qbeta 缀合物
  • 批准号:
    10201474
  • 财政年份:
    2019
  • 资助金额:
    $ 23.3万
  • 项目类别:
Synthetic glycan conjugates with bacteriophage Qbeta for broad spectrum anti-salmonella vaccines
用于广谱抗沙门氏菌疫苗的合成聚糖与噬菌体 Qbeta 缀合物
  • 批准号:
    10653943
  • 财政年份:
    2019
  • 资助金额:
    $ 23.3万
  • 项目类别:
Virus like particles as carriers for carbohydrate based anti-Salmonella vaccines
病毒样颗粒作为碳水化合物抗沙门氏菌疫苗的载体
  • 批准号:
    9118056
  • 财政年份:
    2015
  • 资助金额:
    $ 23.3万
  • 项目类别:
Virus like particles as carriers for carbohydrate based anti-Salmonella vaccines
病毒样颗粒作为碳水化合物抗沙门氏菌疫苗的载体
  • 批准号:
    8823965
  • 财政年份:
    2015
  • 资助金额:
    $ 23.3万
  • 项目类别:
Rabbit model to assess reactogenicity and immunogenicity of Salmonella vaccines
用于评估沙门氏菌疫苗反应原性和免疫原性的兔模型
  • 批准号:
    8607893
  • 财政年份:
    2013
  • 资助金额:
    $ 23.3万
  • 项目类别:
Rabbit model to assess reactogenicity and immunogenicity of Salmonella vaccines
用于评估沙门氏菌疫苗反应原性和免疫原性的兔模型
  • 批准号:
    8490135
  • 财政年份:
    2013
  • 资助金额:
    $ 23.3万
  • 项目类别:
Evaluation of Protein Channel-Attenuated Salmonella Vaccines
蛋白质通道减毒沙门氏菌疫苗的评价
  • 批准号:
    7849975
  • 财政年份:
    2009
  • 资助金额:
    $ 23.3万
  • 项目类别:
Evaluation of Protein Channel-Attenuated Salmonella Vaccines
蛋白质通道减毒沙门氏菌疫苗的评价
  • 批准号:
    7661304
  • 财政年份:
    2009
  • 资助金额:
    $ 23.3万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了